Kim; Hye-Nan

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kim; Hye-Nan.The latest application filed is for "antibody to programmed cell death 1 (pd-1) and use thereof".

Company Profile

2.8.13

Kim; Hye-Nan - Daejeon KR
Kim; Hye Nan - Seosan-si KR
Kim; Hye Nan - Yuseong-gu KR
Kim; Hye Nan - Yuseong-gu Daejeon KR
Kim; Hye Nan - Dong-gu KR
KIM; Hye Nan - Daegeon KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antibody to programmed cell death 1 (PD-1) and use thereof Grant 11,248,048 - Park , et al. February 15, 2	2022-02-15
Antibody To Programmed Cell Death 1 (pd-1) And Use Thereof App 20190248900 - Park; Jae Eun ; et al.	2019-08-15
Modified DKK2 protein, nucleic acid encoding the same, preparation method thereof, and use thereof Grant 10,259,850 - Ha , et al.	2019-04-16
Modified Dkk2 Protein, Nucleic Acid Encoding The Same, Preparation Method Thereof, And Use Thereof App 20180016313 - HA; Il Ho ; et al.	2018-01-18
Anti-c-Met antibody having HGF activity and use thereof Grant 9,631,020 - Park , et al. April 25, 2	2017-04-25
Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient Grant 9,388,223 - Lee , et al. July 12, 2	2016-07-12
Drug conjugate comprising drug linked to human c-Met antibody, and use therefor Grant 9,364,556 - Park , et al. June 14, 2	2016-06-14
Drug Conjugate Comprising Drug Linked To Human C-met Antibody, And Use Therefor App 20150110815 - Park; Young Woo ; et al.	2015-04-23
Myostatin Inhibitor Comprising Extracellular Water-Soluble Domains of DLK1 As Active Ingredient App 20150030595 - Lee; Dong Hee ; et al.	2015-01-29
Anti-c-met Antibody Having Hgf Activity And Use Thereof App 20140193431 - Park; Young Woo ; et al.	2014-07-10
Activin Receptor Type II B Inhibitors Comprising DLK1 Extracellular Water-Soluble Domain App 20140072558 - Park; Young Woo ; et al.	2014-03-13
Obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient Grant 8,183,405 - Kwon , et al. May 22, 2	2012-05-22
Cinnamaldehyde derivatives having improved solubility in water, a method for preparing the same and a pharmaceutical composition comprising the same Grant 7,939,542 - Kwon , et al. May 10, 2	2011-05-10
Composition For The Treatment Of Diabetes And Metabolic Syndrome Containing Obovatol And Its Synthesized Derivatives App 20100125103 - Huh; Tae-Lin ; et al.	2010-05-20
Novel Cinnamaldehyde Derivatives Having Improved Solubility In Water, A Method For Preparing The Same And A Pharmaceutical Composition Comprising The Same App 20090325972 - KWON; Byoung Mog ; et al.	2009-12-31
Composition Comprising Extracts Or Fractions Of Magnolia Obovata Thunb For Treating And Preventing Inflammation Disease App 20090311354 - KWON; Byoung-Mog ; et al.	2009-12-17
Composition For The Treatment Of Cancers And Inhibition Of Metastasis Containing Extracts Or Fractions Of The Magnolia Obovata App 20090263521 - KWON; Byoung-Mog ; et al.	2009-10-22
Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient App 20090239955 - Kwon; Byoung-Mog ; et al.	2009-09-24

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.